Botox vs Other Botulinum Toxins: Key Differences Explained

While Botox and botulinum are often used synonymously, they are in fact different. Botox is a specific drug manufactured by Allergan, while botulinum toxin is a neurotoxic compound produced by Clostridium botulinum. Understanding Botox vs other Botulinum toxins is important because different products can vary in formulation, protein content, dosing, onset of action, and other clinical characteristics.

As Botox remains one of the most widely used botulinum toxin products in aesthetic medicine, many practices choose to buy Botox online as part of routine product sourcing. Product authenticity, appropriate storage, and proper handling remain important considerations when purchasing prescription injectables.

The primary compound of Botox, which is derived from botulinum, is known as onabotulinumtoxinA. Its primary mechanism of action is the relaxation of muscles and the blocking of pain impulses from the brain.

Botox was the first drug to be approved by the Food and Drug Administration (FDA) for treating facial wrinkles. It is used to ‘freeze’ facial wrinkles that are caused by the breakdown of collagen within the skin.

Other firms are exploiting the clinical benefits of botulinum and manufacturing their own products. While the results can be the same, there are significant differences between the classic Botox and other Botulinum toxins.

In addition to Botox, there are several injectables that have been created that utilize onabotulinumtoxinA, such as Dysport, Xeomin, and Azzalure. These products contain the same therapeutic amounts of onabotulinumtoxin A (150kD) but have key differences.

Botox, along with botulinum toxin type A, contains a 900kD protein complex. It is the only product on the market that has high amounts of proteins (clostridial) with five nanograms per 100-unit vial. It is widely used to treat facial wrinkles and is the first to be commercially manufactured.

Botox vs Other Botulinum Toxins: Key Differences

Let’s examine how other botulinum toxin injectables differ in their composition, onset of action, and treatment costs.

A closer look at Botox vs other Botulinum toxins shows that even products based on botulinum toxin type A can differ in molecular composition, accessory proteins, dosing, and treatment characteristics.

Azzalure

Azzalure contains approximately 4.5 nanograms of clostridium protein per 500-unit vial. It acts similarly to Botox but requires fewer injections than other commercial botulinum toxins.

Several studies have shown that the difference between Azzalure and Botox is not significant. One of the primary differences is the molecular size. Botox has a larger molecular structure than Azzalure, which makes it more accurate in treating conditions because it does not spread far away from the treatment site.

Even though a greater number of injections are required when using Botox, it is considered more effective than Azzalure.

Dysport

Similar to Azzalure, Dysport also contains 4.5 nanograms of clostridium protein (1) per 500-unit vial. It is primarily used to treat the progression of glabellar lines with age.

Dysport treatment is ideal for mild, moderate, and severe glabellar lines. The Food and Drug Administration (FDA) recommends approximately 50 units for glabellar lines divided into five injection sites, whereas the appropriate Botox dosage may differ depending on the treatment area, muscle activity, and individual patient needs.

This means that Botox is more effective than Dysport for treating these wrinkles.

Ipsen Biopharmaceuticals in Paris, France manufactures both Dysport and Azzalure.

Xeomin

Out of all the botulinum toxins, Xeomin contains the smallest amount of clostridial protein at 0.6 nanograms per 100-unit vial. This product does not trigger significant immune response when compared to similar commercial products and does not contain additives that require refrigeration.

Often referred to as a “naked injectable”, Xeomin has fewer side effects and does not require cold storage when compared to Botox, but its onset takes longer. It takes approximately four days for the drug to show its effects, whereas Botox’s results appear in less than 72 hours.

Bocouture

A new product approved by European regulatory authorities is Bocouture. It is used to treat upper facial lines, glabellar lines, and horizontal frown lines.

Bocouture contains 0.6 nanograms of clostridium protein and is similar to Xeomin because both are manufactured by Merz Pharmaceuticals in Frankfurt, Germany. Like Xeomin, it does not have any active proteins encapsulating the drug.

Bocouture contains significantly less clostridial proteins than Botox.

Conclusion

When comparing Botox vs other Botulinum toxins, several commercially available products share a similar mechanism of action but differ in formulation, protein content, dosing, and onset of effect. On the market for several years, it has developed an extensive fanbase and excellent brand value.

While Botox, Dysport, Xeomin, Azzalure and Bocouture are all proven to safely and effectively treat facial wrinkles, the former’s high percentage of proteins means that, on average, fewer injections are needed. This results in a more comfortable – and affordable – experience for the patient. Additionally, the results of Botox appear more quickly than the results of some other botulinum toxin products, making it an even more competitive choice.

FAQ

What should practitioners know about Botox vs other Botulinum toxins?

Botox is a specific brand of botulinum toxin type A, while products such as Dysport, Xeomin, Azzalure, and Bocouture use related formulations. They can differ in protein content, molecular characteristics, onset of action, storage requirements, and dosing.

Is Xeomin the same as Botox?

No. Xeomin and Botox both use botulinum toxin type A, but their formulations are different. Xeomin contains fewer accessory proteins and is often described as a “naked injectable.” It also does not require the same refrigeration conditions as Botox.

Which lasts longer: Botox or Dysport?

Both Botox and Dysport provide temporary results, and treatment duration can vary depending on the patient, dose, and treatment area. The article notes that Botox may require fewer units for some applications, while Dysport can have different diffusion and dosing characteristics.

Citations

[1] Allergan Aesthetics. BOTOX Cosmetic (OnabotulinumtoxinA) for Injection: Prescribing Information. Revised Oct. 2024, U.S. Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdf.

[2] U.S. Food and Drug Administration. “Botulinum Toxin Type A – Product Approval Information.” 12 Apr. 2002, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/botuall041202L.htm.

[3] Ipsen Biopharmaceuticals, Inc. DYSPORT® (AbobotulinumtoxinA) for Injection: Prescribing Information. Revised Sept. 2023, U.S. Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125274s125lbl.pdf.

[4] Merz Pharmaceuticals, LLC. XEOMIN® (IncobotulinumtoxinA) for Injection: Prescribing Information. 2026, U.S. Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125360s110lbl.pdf.

[5] Galderma (U.K.) Limited. Azzalure, 125 Speywood Units, Powder for Solution for Injection: Summary of Product Characteristics. Electronic Medicines Compendium, updated 12 Feb. 2026, https://www.medicines.org.uk/emc/product/6584/smpc.

[6] Merz Aesthetics UK Ltd. BOCOUTURE 50 Units Powder for Solution for Injection: Summary of Product Characteristics. Electronic Medicines Compendium, updated 19 Jan. 2026, https://www.medicines.org.uk/emc/product/600/smpc.

[7] Frevert, Jürgen. “Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.” Drugs in R&D, vol. 10, no. 2, 2010, pp. 67-73. https://doi.org/10.2165/11584780-000000000-00000